A recent JAMA Oncology study highlights the power of the open-access model GenomeDx has pursued since launching its Decipher prostate cancer prognostic.
The PAM50 breast cancer classifier successfully split prostate cancer samples into luminal and basal subtypes with ties to patient outcomes and treatment response.
The company published a new study of average- and high-risk patients showing that the test better predicted metastasis in patients treated with radiation and hormonal therapy.
GenomeDx will use its Decipher Classifier and Genomics Resource Information Database to analyze samples, for tumor aggressiveness, and identify predictive signatures.
Results from a study using the database showed that patients with high expression of a certain gene signature had better outcomes with radiation therapy than without it.
Researchers are using GenomeDx's database to improve understanding of the genomic underpinnings of prostate cancer and advance personalized treatment strategies.
Launching the new biopsy-based version of Decipher, GenomeDx enters more direct competition with tests offered by Myriad Genetics and Genomic Health.
The firm will provide whole-genome profiling for Cedars-Sinai prostate cancer patients, who will also be tested with the Decipher Prostate Cancer Classifier.
The test is designed to predict prostate cancer aggressiveness and launched in the US in 2013.
The cloud-based Decipher GRID database will hold anonymized genomic data from the company's Decipher test and make it available to participating cancer centers.
The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.
Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.
Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.
In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.